Works matching AU Mikus, Gerd

Results: 162
    1

    Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.

    Published in:
    OncoImmunology, 2015, v. 4, n. 4, p. 00, doi. 10.1080/2162402X.2014.1001217
    By:
    • Schmitz-Winnenthal, Friedrich H;
    • Weitz, Jürgen;
    • Ulrich, Alexis;
    • Buechler, Markus W;
    • Pianka, Frank;
    • Klaiber, Ulla;
    • Diener, Markus;
    • Leowardi, Christine;
    • Schimmack, Simon;
    • Sisic, Leila;
    • Keller, Anne-Valerie;
    • Koc, Ruhan;
    • Knebel, Philipp;
    • Schmidt, Thomas;
    • Hohmann, Nicolas;
    • Mikus, Gerd;
    • Haefeli, Walter E;
    • Niethammer, Andreas G;
    • Breiner, Klaus M;
    • Friedrich, Tobias
    Publication type:
    Article
    2
    3
    4

    Oral bioavailability of microdoses and therapeutic doses of midazolam as a 2-dimensionally printed orodispersible film in healthy volunteers.

    Published in:
    European Journal of Clinical Pharmacology, 2022, v. 78, n. 12, p. 1965, doi. 10.1007/s00228-022-03406-y
    By:
    • Breithaupt, Mareile H.;
    • Krohmer, Evelyn;
    • Taylor, Lenka;
    • Koerner, Eva;
    • Hoppe-Tichy, Torsten;
    • Burhenne, Juergen;
    • Foerster, Kathrin I.;
    • Dachtler, Markus;
    • Huber, Gerald;
    • Venkatesh, Rakesh;
    • Eggenreich, Karin;
    • Czock, David;
    • Mikus, Gerd;
    • Blank, Antje;
    • Haefeli, Walter E.
    Publication type:
    Article
    5
    6
    7

    Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials.

    Published in:
    European Journal of Clinical Pharmacology, 2017, v. 73, n. 4, p. 409, doi. 10.1007/s00228-016-2189-8
    By:
    • Breithaupt-Groegler, Kerstin;
    • Coch, Christoph;
    • Coenen, Martin;
    • Donath, Frank;
    • Erb-Zohar, Katharina;
    • Francke, Klaus;
    • Goehler, Karin;
    • Iovino, Mario;
    • Kammerer, Klaus;
    • Mikus, Gerd;
    • Rengelshausen, Jens;
    • Sourgens, Hildegard;
    • Schinzel, Reinhard;
    • Sudhop, Thomas;
    • Wensing, Georg
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.

    Published in:
    BMC Cancer, 2012, v. 12, n. 1, p. 361, doi. 10.1186/1471-2407-12-361
    By:
    • Niethammer, Andreas G.;
    • Lubenau, Heinz;
    • Mikus, Gerd;
    • Knebel, Philipp;
    • Hohmann, Nicolas;
    • Leowardi, Christine;
    • Beckhove, Philipp;
    • Akhisaroglu, Mustafa;
    • Ge, Yingzi;
    • Springer, Marco;
    • Grenacher, Lars;
    • Buchler, Markus W.;
    • Koch, Moritz;
    • Weitz, Jürgen;
    • Haefeli, Walter E.;
    • Schmitz-Winnenthal, Fridrich H.
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45

    Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841].

    Published in:
    Malaria Journal, 2005, v. 4, p. 45, doi. 10.1186/1475-2875-4-45
    By:
    • Meissner, Peter E.;
    • Mandi, Germain;
    • Witte, Steffen;
    • Coulibaly, Boubacar;
    • Mansmann, Ulrich;
    • Rengelshausen, Jens;
    • Schiek, Wolfgang;
    • Jahn, Albrecht;
    • Sanon, Mamadou;
    • Tapsoba, Théophile;
    • Walter-Sack, Ingeborg;
    • Mikus, Gerd;
    • Burhenne, Jürgen;
    • Riedel, Klaus-Dieter;
    • Schirmer, Heiner;
    • Kouyaté, Bocar;
    • Müller, Olaf
    Publication type:
    Article
    46
    47
    48

    Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach.

    Published in:
    Cardiovascular Drugs & Therapy, 2024, v. 38, n. 4, p. 747, doi. 10.1007/s10557-023-07443-2
    By:
    • Lenard, Alexander;
    • Hermann, Simon A.;
    • Stoll, Felicitas;
    • Burhenne, Juergen;
    • Foerster, Kathrin I.;
    • Mikus, Gerd;
    • Meid, Andreas D.;
    • Haefeli, Walter E.;
    • Blank, Antje
    Publication type:
    Article
    49
    50